Esterified Estrogens, Methyltestosterone side effects: what 371 FDA adverse event reports show

Esterified Estrogens, Methyltestosterone · 6 reaction terms · 147 drug–reaction co-reports · data 2026-09-14

Drug class

Androgen

FDA label (Established Pharmacologic Class) · compare the class

Who reports

371 reports · 75% serious · 12 with death outcome · 99% female

openFDA FAERS counts, all years, deduplication not applied

Used for

5- Indication ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE HALF STRENGTH are indicated in the treatment of: Moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that.

FDA label, Indications and Usage

What it is

1- Product Name: Esterified Estrogens and Methyltestosterone Tablets 2- Name and Strength of the active Ingredient (s)

FDA label, Description section

Boxed warning

1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA Three independent case-control studies have reported an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for prolonged periods. This risk was independent of the other known risk factors for endometrial cancer.

FDA label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 5 strongest signals

Labeled adverse reaction 1Labeled (related wording) 2Not in label — unassessed 2

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Breast cancer female	69	145.4 117.4–179.9ROR 178.3 · χ² 9,735 / p <1e-300	139.5 EB05 114.0 · IC025 +5.8 3/3 methods agree	Labeled (related wording) related wording	serious PRR 112.6	no trial data cached
Ovarian cancer	10	61.1 33.1–112.6ROR 62.7 · χ² 532 / p 5e-118	55.0 EB05 31.9 · IC025 +2.9 3/3 methods agree	Not in label — unassessed	serious PRR 47.2	no trial data cached
Breast cancer metastatic	11	58.0 32.4–103.9ROR 59.7 · χ² 560 / p 4e-124	52.9 EB05 31.5 · IC025 +3.0 3/3 methods agree	Labeled (related wording) related wording	serious PRR 45.6	no trial data cached
Breast cancer	47	28.3 21.6–36.9ROR 32.2 · χ² 1,213 / p 4e-266	28.0 EB05 21.9 · IC025 +4.0 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 21.9	no trial data cached
Pharmaceutical product complaint	6	12.9 5.8–28.5ROR 13.1 · χ² 54 / p 8e-14	9.3 EB05 3.8 · IC025 +1.3 3/3 methods agree	Not in label — unassessed	serious PRR 16.0	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Breast cancer female	69	145.4 117.4–179.9ROR 178.3 · χ² 9,735 / p <1e-300	139.5 EB05 114.0 · IC025 +5.8 3/3 methods agree	Labeled (related wording) related wording	serious PRR 112.6	no trial data cached
Breast cancer	47	28.3 21.6–36.9ROR 32.2 · χ² 1,213 / p 4e-266	28.0 EB05 21.9 · IC025 +4.0 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 21.9	no trial data cached
Breast cancer metastatic	11	58.0 32.4–103.9ROR 59.7 · χ² 560 / p 4e-124	52.9 EB05 31.5 · IC025 +3.0 3/3 methods agree	Labeled (related wording) related wording	serious PRR 45.6	no trial data cached
Ovarian cancer	10	61.1 33.1–112.6ROR 62.7 · χ² 532 / p 5e-118	55.0 EB05 31.9 · IC025 +2.9 3/3 methods agree	Not in label — unassessed	serious PRR 47.2	no trial data cached
Pharmaceutical product complaint	6	12.9 5.8–28.5ROR 13.1 · χ² 54 / p 8e-14	9.3 EB05 3.8 · IC025 +1.3 3/3 methods agree	Not in label — unassessed	serious PRR 16.0	no trial data cached
Sexual dysfunction	4	19.4 7.3–51.3ROR 19.6 · χ² 53 / p 2e-13	13.3 EB05 3.7 · IC025 +0.9 3/3 methods agree	Not in label — unassessed	serious PRR 22.3	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Esterified Estrogens, Methyltestosterone?

In FDA FAERS, the most frequently co-reported reaction terms for Esterified Estrogens, Methyltestosterone are breast cancer female, breast cancer, breast cancer metastatic, ovarian cancer, pharmaceutical product complaint, sexual dysfunction. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Esterified Estrogens, Methyltestosterone have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: 1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA Three independent case-control studies have reported an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for prolonged periods. This risk was independent of the other known risk factors for endometrial cancer.

Do FAERS signals prove that Esterified Estrogens, Methyltestosterone causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 289c9515-f17a-4d53-9230-d3aede01bf54, effective 20260121; matched on openfda.generic_name.exact:"ESTERIFIED ESTROGENS, METHYLTESTOSTERONE")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 6 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.